Results 181 to 190 of about 7,199,374 (204)

Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]

Biological Psychiatry, 2021
Elizabeth Merikle, Vanessa Patel, Thomas Dobbins, Stephen OQuinn, Nancy Tich, Joseph Palumbo   +5 more
openaire   +1 more source

Harmless Molecules in Supplemental Therapy in COVID-19 and Fragile X Syndrome (FXS)

2022
Altable, Marcos, Walaa Fikry
openaire   +1 more source

Fragile x syndrome: Explanatory models for the cause of FXS in Cameroon, a qualitative study

2020
Kamga, Karen Kengne, De Vries, Jantina, Nguefack, Séraphin, Nchangwi Syntia Munung, Wonkam, Ambroise   +4 more
openaire   +1 more source

Fragile X Syndrome (FXS)

2013
Tracey Ward, Raphael Bernier, Cora Mukerji, Danielle Perszyk, James C. McPartland, Ellen Johnson, Susan Faja, Maureen Nevers, Thomas Frazier, Patricia Howlin, Sarah Savage, Thomas Zane, Traci Lanner, Michelle Myers, Ernst VanBergeijk, Samantha Huestis, Nirit Bauminger-Zviely, Peter Doehring, Guus Voorst, Kelly Macy, Jennifer M. Kwon, Edward McNulty, S. Michael Chapman, Michael J. Crowley, Allison Bean, Susan Hyman, Lawrence David Scahill, Lorna Wing, A. Charles Catania, John Thorne, Usha Kini, Maura Moyle, Claire Plowgian, Francesca Happé, Jane Case-Smith, Lauren Schmitt, Moira Lewis, Mary Jane Weiss, Jan Van der Rutger Gaag, Hillary Hurst, Laura Bonazinga, Diane R. Paul, Francesca Happé, Carolyn A. Doyle, Christopher J. McDougle, Kate S. Perri, Marcel Moran, Kimberly Stigler, Christopher J. McDougle, Susan Hyman, Margaret St. John, David Hessl, Andrea Schneider, Juli Katon, Hillary Hurst, Nirit Bauminger-Zviely, Nouchine Hadjikhani, Nicole Rinehart, Peter Enticott, John Bradshaw, Mark Palmieri, Robert LaRue, John Molteni, Robert LaRue, Mark Palmieri, Patricia Prelock, Ralph-Axel Müller, Robert LaRue, Shaunessy Egan, Dawn Hendricks, Katherin C. Holman, Kristen D’Eramo, Susan Faja, Danielle Perszyk   +73 more
openaire   +1 more source

A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]

Biological Psychiatry, 2021
Elizabeth Berry-Kravis, Randi Hagerman, Dejan Budimirovic, Craig Erickson, Helen Heussler, Nicole Tartaglia, Jonathan Cohen, Thomas Dobbins, Elizabeth Merikle, Terri Sebree, Nancy Tich, Joseph Palumbo   +11 more
openaire   +1 more source

Burden of Illness Among Patients With Fragile X Syndrome (FXS): A Medicaid Perspective.

Current Medical Research and Opinion, 2016
Jessica Marvel, James Signorovitch, Maryna Marynchenko   +2 more
exaly  

Development of Mavoglurant and Its Potential for the Treatment of Fragile X Syndrome

Expert Opinion on Investigational Drugs, 2014
Randi J. Hagerman, Sébastien Jacquemont, Elizabeth Berry-Kravis   +2 more
exaly  

Arbaclofen Treatment Is Associated with Global Behavioral Improvement in Fragile X Syndrome (FXS): Results of a Randomized, Controlled Phase 2 Trial

Journal of Developmental & Behavioral Pediatrics, 2010
Lulu Wang, Randi Hagerman, Barbara Rathmell, Paul Wang, Elizabeth Berry-Kravis   +4 more
openaire   +1 more source

Cannabidiol Transdermal Gel for the Treatment of Fragile X Syndrome: Post hoc Responder Analysis and Pattern of Efficacy on domains of the Aberrant Behavior Checklist-FXS (ABC-CFXS) (4743)

Neurology, 2020
Joseph Palumbo, Wei Du, Helen Heussler, Natalie Silove, Jonathan Cohen   +4 more
openaire   +1 more source

Development of a Fragile X Syndrome (FXS) Knowledge Scale: Towards a Modified Multidimensional Measure of Informed Choice for FXS Population Carrier Screening

Health Expectations, 2015
Obioha C Ukoumunne, Alison D Archibald, Jon D Emery   +2 more
exaly